Improving the Health of Persons With Serious Mental Illness
Persons with serious mental illness have a high rate of early mortality. Contributing factors include increased prevalence of smoking and other forms of substance abuse, sedentary lifestyle, and adverse effects of psychotropic medication use. These greater risks for premature death are compounded by poor access to medical care. Some individuals with serious mental illness are uncomfortable seeking care at physical health sites, and most mental health sites do not have the capability of providing needed physical health care. sons taking antipsychotic medications, in a yearlong period. Overall, 30.1% of individuals were screened. It would be fair to point out that the efficacy of screening for diabetes has not been well established. However, that less than one-third had such screening for a known adverse effect of antipsychotic medication use suggests opportunities for improvement in integrated health care. Among those who had at least 1 primary care visit during the year, the proportion screened was significantly higher at 35.6% vs 19.8% for those who had no primary care visit.
To improve care for persons with serious mental illness, it will be necessary to break down the silos that separate the mental health and physical health care systems. Integrated care (care provided by a team of physical and mental health clinicians)-or at least colocated care (care provided by physical and mental health clinicians in the same place)-offers the promise of improving the physical health of individuals with mental illness, as well as the mental health of those seeking physical health services.
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LESS IS MORE

Use of Intra-aortic Balloon Pump in a Japanese Multicenter Percutaneous Coronary Intervention Registry
We read with interest the recent meta-analysis by Ahmad et al, 1 demonstrating a negative association between intraaortic balloon pump (IABP) therapy and mortality among patients experiencing acute m y o c a r d i a l i n f a r c t i o n . We agree that efforts are needed to clarify the role of IABP therapy and to examine its effect on care in other regions and countries. In Japan, IABP therapy is frequently used in patients with guideline-based indications and in patients with less established indications, and the judicious use of invasive procedures has been highlighted. 2, 3 Our objective herein was to investigate the prognostic effect of IABP use in patients undergoing percutaneous coronary intervention (PCI) for nonacute and acute indications registered in a contemporary multicenter Japanese PCI registry (Japan Cardiovascular Database-Keio Interhospital Cardiovascular Studies 4 ).
Methods | We analyzed data from 14 378 consecutive patients treated between September 2, 2008, and May 19, 2014. Of those, 1124 patients were excluded because of missing baseline information (n = 192), registration for staged PCI during the same hospitalization (n = 801), or PCI performed under percutaneous cardiopulmonary support (n = 132). The remaining 13 253 patients were included herein, and logistic regression models for in-hospital mortality were used to correct for differences in variables. We included in the logistic regression model all variables exhibiting a significant (P < .10) bivariate association with IABP use. Baseline inequality between patients with and without IABPs was evaluated with the baseline inequality index, the same method used by Ahmad et al. 1 Because our study focused on the effect of IABP on in-hospital mortality for all PCIs, we redefined a list of baseline characteristics recognized as markers of mortality risk based on a previous study. Results | Baseline demographics in patients with and without IABPs are summarized in the Table. Overall, PCIs after STsegment elevation myocardial infarctions and PCIs after non-ST-segment elevation myocardial infarctions or unstable angina accounted for 23.9% and 24.2% of the procedures, respectively. Before PCI, 486 patients (3.7%) and 900 patients (6.8%) manifested complications of cardiogenic shock and serious heart failure (New York Heart Association functional classification ≥3), respectively. The proportions of interventions for left main trunk and 3-vessel disease were 3.7% and 0.9%, respectively. Intra-aortic balloon pumps were inserted in 885 patients (6.7%). There were 134 in-hospital deaths (15.1%) among the patients receiving an IABP and 111 inhospital deaths (0.9%) among the patients not receiving an IABP. In the crude analysis, the use of IABP was associated with an increased risk of in-hospital mortality (Figure, A) . Intra-aortic balloon pump use remained an independent predictor of in-hospital mortality after adjusting for baseline differences (odds ratio, 3.87; 95% CI, 2.71-5.52; P < .001). Among several subgroups thought to potentially have indications for IABP use, the use of IABPs was consistently associated with risk of in-hospital death (Figure, B) , and IABP recipients had a worse baseline risk profile than nonrecipients (Figure, C) . Notably, the risk of death appeared to be higher (with higher odds ratios) as the indications for IABP use became less established.
Discussion | Among a cohort of Japanese patients undergoing PCI in whom IABP use was frequent, we found that the use of IABP was associated with a higher risk of in-hospital death. This
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